ArticlePharmacoEconomics2016
Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial.
Article in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Costs of Influenza Illness and Acute Respiratory Infections by Household Income Level: Catastrophic Health Expenditures and Implications for Health Equity.Influenza and other respiratory viruses · 2025Pooled it
- [Evolution and Application of Disease Control Priorities].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Pooled it
- Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review.International journal of environmental research and public health · 2022Pooled it
- Pooled it
- Cost of Differentiated HIV Antiretroviral Therapy Delivery Strategies in Sub-Saharan Africa: A Systematic Review.Journal of acquired immune deficiency syndromes (1999) · 2019Pooled it
- Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.Social science & medicine (1982) · 2018Pooled it
- An extended cost-effectiveness analysis of decentralised TB diagnostic testing with Molbio Truenat MTB/RIF versus hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania.BMJ global health · 2025Trial
- Trial
- Trial
- Invisibility problem: why current economic evaluations understate the value of sexual and reproductive health and rights, and three strategic shifts to address it.BMJ global health · 2026Article
- Lives saved and financial risk protectionfrom scaling up kangaroo mother care in India: an extended cost -effectivenessanalysis.BMJ global health · 2026Article
- A Novel Decision-Modeling Framework for Health Policy Analyses When Outcomes Are Influenced by Social and Disease Processes.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Estimating the distributional impact of improving access to snake antivenom in urban and rural Lao People's Democratic Republic: An extended cost-effectiveness analysis.PLoS neglected tropical diseases · 2026Article
- Harnessing health economic evaluation for policy and practice.Communications medicine · 2026Review
- Article
- Incorporating an equity perspective in systematic reviews of interventions: potential methodological approaches.Journal of epidemiology and community health · 2026Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Estimating the global macroeconomic impact of colorectal cancer: evidence from Global Burden of Disease 2021 and Value of a Statistical Life Year framework.International journal of surgery (London, England) · 2026Article
- From the rare to the essential: analyzing the needs of physicians and families managing rare diseases.BMC health services research · 2026Article
- How to Fix a Broken Health Care System: Pathways to Maximize Health and Well-being for All.Diabetes care · 2026Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health policy instruments such as the public financing of health technologies (e.g., new drugs, vaccines) entail consequences in multiple domains. Fundamentally, public health policies aim at increasing the uptake of effective and efficient interventions and at subsequently leading to better health benefits (e.g., premature mortality and morbidity averted). In addition, public health policies can provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, public policies such as social and health insurance programs can prevent illness-related impoverishment and procure financial risk protection. Furthermore, public policies can improve the distribution of health in the population and promote the equalization of health among individuals. Extended cost-effectiveness analysis was developed to address health policy assessment, specifically to evaluate the health and financial consequences of public policies in four domains: (1) the health gains; (2) the financial risk protection benefits; (3) the total costs to the policy makers; and (4) the distributional benefits. Here, we present a tutorial that describes both the intent of extended cost-effectiveness analysis and its keys to allow easy implementation for health policy assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.